Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa

por Abou-Alfa, Ghassan
Publicado 2020

ESMO presidential symposium wrap up: the ClarIDHy trial

por Abou-Alfa, Ghassan K
Publicado 2020

Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management

por Abou-Alfa, Ghassan K., Norton, Larry
Publicado 2023

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

por Dika, Imane El, Abou-Alfa, Ghassan K.
Publicado 2017

Hepatocellular carcinoma, novel therapies on the horizon

por El Dika, Imane, Makki, Iman, Abou-Alfa, Ghassan K.
Publicado 2020

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

por Costa, Frederico, Wiedenmann, Bertram, Roderburg, Christoph, Mohr, Raphael, Abou‐Alfa, Ghassan K.
Publicado 2023

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

por Bibeau, Kristen, Féliz, Luis, Lihou, Christine F., Ren, Haobo, Abou-Alfa, Ghassan K.
Publicado 2022

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

por Abou-Alfa, Ghassan K., Bibeau, Kristen, Schultz, Nikolaus, Yaqubie, Amin, Millang, Brittanie, Ren, Haobo, Féliz, Luis
Publicado 2022

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines

por Lacouture, Mario E., Sibaud, Vincent, Anadkat, Milan J., Kaffenberger, Benjamin, Leventhal, Jonathan, Guindon, Kathleen, Abou‐Alfa, Ghassan
Publicado 2020

Proportion of cancer in a Middle eastern country attributable to established risk factors

por Charafeddine, Maya A., Olson, Sara H., Mukherji, Deborah, Temraz, Sally N., Abou-Alfa, Ghassan K., Shamseddine, Ali I.
Publicado 2017

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma

por Ji, Jun Ho, Ha, Sang Yun, Lee, Danbi, Sankar, Kamya, Koltsova, Ekaterina K., Abou-Alfa, Ghassan K., Yang, Ju Dong
Publicado 2023

Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma

por Chami, Perla, Jarnagin, William, Abou-Alfa, Ghassan K., Harding, James, Kim, Neal, Lin, Haibo, El Homsi, Maria, Crane, Christopher, Hajj, Carla
Publicado 2023

Hepatocellular Carcinoma in Sub-Saharan Africa

por Kedar Mukthinuthalapati, V. V. Pavan, Sewram, Vikash, Ndlovu, Ntokozo, Kimani, Stephen, Abdelaziz, Ashraf Omar, Chiao, Elizabeth Yu, Abou-Alfa, Ghassan K.
Publicado 2021

Lymph-node ratio is an independent prognostic factor in patients with stage III colorectal cancer: a retrospective study from the Middle East

por Elias, Elias, Mukherji, Deborah, Faraj, Walid, Khalife, Mohammad, Dimassi, Hani, Eloubeidi, Mohamad, Hattoum, Hasan, Abou‒Alfa, Ghassan K, Saleh, Ahmad, Shamseddine, Ali
Publicado 2012

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the...

por El-Khoueiry, Anthony B., Meyer, Tim, Cheng, Ann-Lii, Rimassa, Lorenza, Sen, Suvajit, Milwee, Steven, Kelley, Robin Kate, Abou-Alfa, Ghassan K.
Publicado 2022

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

por Kelley, Robin K., Mollon, Patrick, Blanc, Jean-Frédéric, Daniele, Bruno, Yau, Thomas, Cheng, Ann-Lii, Valcheva, Velichka, Marteau, Florence, Guerra, Ines, Abou-Alfa, Ghassan K.
Publicado 2020

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

por Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Publicado 2021

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors

por Harding, James J., Jungels, Christiane, Machiels, Jean-Pascal, Smith, David C., Walker, Chris, Ji, Tao, Jiang, Ping, Li, Xin, Asatiani, Ekaterine, Van Cutsem, Eric, Abou-Alfa, Ghassan K.
Publicado 2023

Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?

por Faraj, Walid, Alameddine, Raafat, Mukherji, Deborah, Musallam, Khaled, Haydar, Ali, ELoubiedi, Mohamed, Shamseddine, Ali, Halal, Ali, Abou-Alfa, Ghassan K, O’Reilly, Eileen M, Jamali, Faek, Khalife, Mohamed
Publicado 2013

Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report

por Kudelka, Matthew R., Abou-Alfa, Ghassan K., O’Reilly, Eileen M., Foote, Michael B., Sirohi, Bhawna, Elias, Rawad, Shamseddine, Ali, Paroder, Viktoriya, Moussa, Amgad M., Cohen, Paul, Ganesh, Karuna
Publicado 2023